386 related articles for article (PubMed ID: 21124317)
21. Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma.
Diskin SJ; Capasso M; Schnepp RW; Cole KA; Attiyeh EF; Hou C; Diamond M; Carpenter EL; Winter C; Lee H; Jagannathan J; Latorre V; Iolascon A; Hakonarson H; Devoto M; Maris JM
Nat Genet; 2012 Oct; 44(10):1126-30. PubMed ID: 22941191
[TBL] [Abstract][Full Text] [Related]
22.
Zhang J; Lin H; Wang J; He J; Zhang D; Qin P; Yang L; Yan L
Oncotarget; 2017 Sep; 8(39):65620-65626. PubMed ID: 29029458
[TBL] [Abstract][Full Text] [Related]
23. Oncogenic mutations of ALK kinase in neuroblastoma.
Chen Y; Takita J; Choi YL; Kato M; Ohira M; Sanada M; Wang L; Soda M; Kikuchi A; Igarashi T; Nakagawara A; Hayashi Y; Mano H; Ogawa S
Nature; 2008 Oct; 455(7215):971-4. PubMed ID: 18923524
[TBL] [Abstract][Full Text] [Related]
24. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma.
Maris JM; Mosse YP; Bradfield JP; Hou C; Monni S; Scott RH; Asgharzadeh S; Attiyeh EF; Diskin SJ; Laudenslager M; Winter C; Cole KA; Glessner JT; Kim C; Frackelton EC; Casalunovo T; Eckert AW; Capasso M; Rappaport EF; McConville C; London WB; Seeger RC; Rahman N; Devoto M; Grant SF; Li H; Hakonarson H
N Engl J Med; 2008 Jun; 358(24):2585-93. PubMed ID: 18463370
[TBL] [Abstract][Full Text] [Related]
25. Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility.
Capasso M; Diskin SJ; Totaro F; Longo L; De Mariano M; Russo R; Cimmino F; Hakonarson H; Tonini GP; Devoto M; Maris JM; Iolascon A
Carcinogenesis; 2013 Mar; 34(3):605-11. PubMed ID: 23222812
[TBL] [Abstract][Full Text] [Related]
26. Characterization of the Lmo4 gene encoding a LIM-only protein: genomic organization and comparative chromosomal mapping.
Tse E; Grutz G; Garner AA; Ramsey Y; Carter NP; Copeland N; Gilbert DJ; Jenkins NA; Agulnick A; Forster A; Rabbitts TH
Mamm Genome; 1999 Nov; 10(11):1089-94. PubMed ID: 10556429
[TBL] [Abstract][Full Text] [Related]
27. Common genetic variants in NEFL influence gene expression and neuroblastoma risk.
Capasso M; Diskin S; Cimmino F; Acierno G; Totaro F; Petrosino G; Pezone L; Diamond M; McDaniel L; Hakonarson H; Iolascon A; Devoto M; Maris JM
Cancer Res; 2014 Dec; 74(23):6913-24. PubMed ID: 25312269
[TBL] [Abstract][Full Text] [Related]
28. Expression of LIM protein genes Lmo1, Lmo2, and Lmo3 in adult mouse hippocampus and other forebrain regions: differential regulation by seizure activity.
Hinks GL; Shah B; French SJ; Campos LS; Staley K; Hughes J; Sofroniew MV
J Neurosci; 1997 Jul; 17(14):5549-59. PubMed ID: 9204936
[TBL] [Abstract][Full Text] [Related]
29. Somatic structural variation targets neurodevelopmental genes and identifies
Lopez G; Conkrite KL; Doepner M; Rathi KS; Modi A; Vaksman Z; Farra LM; Hyson E; Noureddine M; Wei JS; Smith MA; Asgharzadeh S; Seeger RC; Khan J; Auvil JG; Gerhard DS; Maris JM; Diskin SJ
Genome Res; 2020 Sep; 30(9):1228-1242. PubMed ID: 32796005
[TBL] [Abstract][Full Text] [Related]
30. Replication of neuroblastoma SNP association at the BARD1 locus in African-Americans.
Latorre V; Diskin SJ; Diamond MA; Zhang H; Hakonarson H; Maris JM; Devoto M
Cancer Epidemiol Biomarkers Prev; 2012 Apr; 21(4):658-63. PubMed ID: 22328350
[TBL] [Abstract][Full Text] [Related]
31. Activating mutations in ALK provide a therapeutic target in neuroblastoma.
George RE; Sanda T; Hanna M; Fröhling S; Luther W; Zhang J; Ahn Y; Zhou W; London WB; McGrady P; Xue L; Zozulya S; Gregor VE; Webb TR; Gray NS; Gilliland DG; Diller L; Greulich H; Morris SW; Meyerson M; Look AT
Nature; 2008 Oct; 455(7215):975-8. PubMed ID: 18923525
[TBL] [Abstract][Full Text] [Related]
32. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma.
Capasso M; Devoto M; Hou C; Asgharzadeh S; Glessner JT; Attiyeh EF; Mosse YP; Kim C; Diskin SJ; Cole KA; Bosse K; Diamond M; Laudenslager M; Winter C; Bradfield JP; Scott RH; Jagannathan J; Garris M; McConville C; London WB; Seeger RC; Grant SF; Li H; Rahman N; Rappaport E; Hakonarson H; Maris JM
Nat Genet; 2009 Jun; 41(6):718-23. PubMed ID: 19412175
[TBL] [Abstract][Full Text] [Related]
33. LMO1 is a novel oncogene in colorectal cancer and its overexpression is a new predictive marker for anti-EGFR therapy.
Liu J; Yan P; Jing N; Yang J
Tumour Biol; 2014 Aug; 35(8):8161-7. PubMed ID: 24845030
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma.
Hungate EA; Applebaum MA; Skol AD; Vaksman Z; Diamond M; McDaniel L; Volchenboum SL; Stranger BE; Maris JM; Diskin SJ; Onel K; Cohn SL
J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 29117357
[TBL] [Abstract][Full Text] [Related]
35. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.
Łastowska M; Viprey V; Santibanez-Koref M; Wappler I; Peters H; Cullinane C; Roberts P; Hall AG; Tweddle DA; Pearson AD; Lewis I; Burchill SA; Jackson MS
Oncogene; 2007 Nov; 26(53):7432-44. PubMed ID: 17533364
[TBL] [Abstract][Full Text] [Related]
36. Analysis of neuroblastoma tumour progression; loss of PHOX2B on 4p13 and 17q gain are early events in neuroblastoma tumourigenesis.
Krona C; Carén H; Sjöberg RM; Sandstedt B; Laureys G; Kogner P; Martinsson T
Int J Oncol; 2008 Mar; 32(3):575-83. PubMed ID: 18292934
[TBL] [Abstract][Full Text] [Related]
37. The functional variant rs34330 of CDKN1B is associated with risk of neuroblastoma.
Capasso M; McDaniel LD; Cimmino F; Cirino A; Formicola D; Russell MR; Raman P; Cole KA; Diskin SJ
J Cell Mol Med; 2017 Dec; 21(12):3224-3230. PubMed ID: 28667701
[TBL] [Abstract][Full Text] [Related]
38. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.
Garraway LA; Widlund HR; Rubin MA; Getz G; Berger AJ; Ramaswamy S; Beroukhim R; Milner DA; Granter SR; Du J; Lee C; Wagner SN; Li C; Golub TR; Rimm DL; Meyerson ML; Fisher DE; Sellers WR
Nature; 2005 Jul; 436(7047):117-22. PubMed ID: 16001072
[TBL] [Abstract][Full Text] [Related]
39. Bivalent promoter marks and a latent enhancer may prime the leukaemia oncogene LMO1 for ectopic expression in T-cell leukaemia.
Oram SH; Thoms J; Sive JI; Calero-Nieto FJ; Kinston SJ; Schütte J; Knezevic K; Lock RB; Pimanda JE; Göttgens B
Leukemia; 2013 Jun; 27(6):1348-57. PubMed ID: 23302769
[TBL] [Abstract][Full Text] [Related]
40. Genetic susceptibility to neuroblastoma.
Tolbert VP; Coggins GE; Maris JM
Curr Opin Genet Dev; 2017 Feb; 42():81-90. PubMed ID: 28458126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
